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SUMMARY
The IFITMs inhibit influenza A virus (IAV) replication
in vitro and in vivo. Here, we establish that the
antimycotic heptaen, amphotericin B (AmphoB), pre-
vents IFITM3-mediated restriction of IAV, thereby
increasing viral replication. Consistent with its
neutralization of IFITM3, a clinical preparation of
AmphoB, AmBisome, reduces the majority of
interferon’s protective effect against IAV in vitro.
Mechanistic studies reveal that IFITM1 decreases
host-membrane fluidity, suggesting both a possible
mechanism for IFITM-mediated restriction and
its negation by AmphoB. Notably, we reveal that
mice treated with AmBisome succumbed to a nor-
mally mild IAV infection, similar to animals deficient
in Ifitm3. Therefore, patients receiving antifungal
therapy with clinical preparations of AmphoB may
be functionally immunocompromised and thus more
vulnerable to influenza, as well as other IFITM3-
restricted viral infections.
INTRODUCTION
Influenza epidemics perennially result in significant morbidity
and mortality, with immunocompromised populations being at
particularly high risk. During IAV infection, the viral hemagglutinin
(HA) proteins bind to host cell receptors. Upon endocytosis and
endosomal acidification, the HA protein undergoes a conforma-
tional change leading to fusion of the viral and host membranes.
Viral ribonucleoproteins (vRNPs) then enter the cytosol and
translocate to the nucleus to commence replication (Medina
and Garcı´a-Sastre, 2011).
IFITM1, IFITM2, and IFITM3 comprise a family of restriction
factors that possess broad antiviral activities (Brass et al.,
2009; Jiang et al., 2010; Mudhasani et al., 2013). IFITM3 is
most active against IAV and resides in late endosomes and lyso-
somes, while IFITM1 is located on the cell surface and blocks
hepatitis C virus (HCV) and the filoviruses Ebola and Marburg
(Feeley et al., 2011; Huang et al., 2011; Wilkins et al., 2013).
The IFITM proteins aremembers of the CD225 protein superfam-
ily and contain two intramembrane domains (IM1 and IM2),
which traverse through the cytosolic-facing leaflet of the lipid
bilayer and are joined by a conserved intracellular loop (Yount
et al., 2012). IFITM3 plays a critical role in vivo because Ifitm3/
mice succumb to a normally mild IAV infection (Bailey et al.,
2012; Everitt et al., 2012). Furthermore, individuals with a variant
of IFITM3 are more likely to suffer a worse course of influenza
(Everitt et al., 2012; Zhang et al., 2013). IFITM3 accounts for
50% to 80% of the in vitro protective effects of interferon (IFN)
against IAV and blocks viral particle fusion subsequent to
endocytosis, thereby preventing the cytosolic entry and nuclear
translocation of vRNPs (Feeley et al., 2011; Huang et al., 2011;
Weidner et al., 2010). The IFITMs thus represent a restriction
factor family of growing translational importance that protects
the host at the earliest stages of infection (Diamond and Farzan,
2013; Perreira et al., 2013).
Several efforts have recently investigated the mechanism of
IFITM-mediated restriction. For example, it has been reported
that the IFITMs decrease membrane fluidity and block viral-en-
velope-induced hemifusion, the latter conclusion predicated on
the alleviation of an IFITM block to cell-to-cell fusion by oleic
acid (Li et al., 2013). Moreover, it has been postulated that the
IFITMs inhibit VSV-g-mediated fusion by disrupting normal lipid
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trafficking, resulting in elevated levels of cholesterol in the late
endosomal and lysosomal membranes (Amini-Bavil-Olyaee
et al., 2013). This last observation may arise from a direct inter-
action between the IM2 domains of IFITM1, IFITM2, and IFITM3
and the endocytic trafficking protein vesicle-associated mem-
brane protein A (VAPA). IFITM binding to VAPA may interfere
with the interaction of VAPA with oxysterol binding protein
(OSBP), a known regulator of cholesterol trafficking (Wyles
et al., 2002). Therefore, IFITMs are envisioned to compete with
OSBP for binding to VAPA, producing elevated levels of choles-
terol that block viral fusion.
While treating fungal infection of our tissue culture cells with
the antimycotic AmphoB we noticed that the previous differ-
ences in the levels of IAV infection due to differing levels of
IFITM3were surprisingly erased. AmphoB has been used to treat
systemic fungal infections, including Aspergillosis, since the
1950’s, and its clinical formulations are currently used widely
to treat a growing number of such cases (Bellmann, 2007).
AmphoB’s mechanism of action is thought to involve its binding
to the fungal membrane constituent, ergosterol, leading to pore
formation and ion egress (Bolard, 1986). In the clinic, AmphoB
treatment produces severe side effects because of the forma-
tion of such membrane-spanning pores, which increase in diam-
eter as a function of concentration, with low concentrations
(0.1 mM) permitting Na+ and K+ to traverse and higher levels
(>5 mM) allowing the passage of larger cations (e.g., Ca+2 and
H3O
+). To overcome this toxicity, two liposomal preparations
of AmphoB, AmBisome and Abelcet, were developed, both of
which manifest reduced side effects by preferentially targeting
fungal membranes. AmBisome is thus a first-line therapy for
systemic fungal infections with an estimated $330 million in
annual sales worldwide (Moen et al., 2009). Of note, after
commencement of our investigations, AmphoB was reported
to increase IAV replication in vitro; however, both themechanism
and the in vivo implications of this phenomenon remain obscure
(Roethl et al., 2011). Therefore, intrigued by our observations
regarding IFITM3’s neutralization by AmphoB, we pursued
studies to elucidate both the mechanism of this interaction and
its potential in vivo consequences.
RESULTS
To investigate our observations regarding AmphoB and IFITM3,
we first evaluated the effect of AmphoB on IAV replication
in IFITM-depleted cells. HeLa cervical adenocarcinoma cells
were stably transduced with either of two short hairpin RNAs
(shRNAs) targeting IFITM3 or two negative control shRNAs
against firefly luciferase (Figures 1A and 1B). HeLa cells were
chosen because they express relatively high levels of endoge-
nous IFITM3 and differing endogenous levels of IFITM3 strongly
correlate with AmphoB’s effects on IAV replication (Feeley et al.,
2011; Roethl et al., 2011). The cell lines were then challenged
with either of two strains of IAV, H1N1 A/WSN/33 (WSN/33) or
H1N1 A/PR/38 (PR8), with or without AmphoB. The loss of
IFITM3 in untreated cells increased the infection of both viruses,
with the enhancement being greater for PR8 (25-fold) than for
WSN/33 (5-fold). In the IFITM3-depleted cells treated with
AmphoB, we saw no increased infection with WSN/33 and a
modest additional increase in replication with PR8 (1.7- and
2.4-fold, respectively), suggesting that the majority of AmphoB’s
enhancement of IAV infection is due to overcoming IFITM3. The
IFITMs act on the viral envelope protein-dependent stage of
entry by blocking fusion. Therefore, we tested the effect of
AmphoB on the infectivity of viral pseudoparticles that express
the HA1, HA5, or HA7 proteins. Consistent with its overcoming
IFITM3, AmphoB treatment enhanced the infectivity of all of
the HA-expressing particles (Figure 1C). Notably, the infectivity
of particles bearing PR8’s HA1 was uniquely increased in the
vector cells treated with AmphoB, suggesting that the residual
infectivity seen when IAV PR8 is used with IFITM3-depleted cells
(Figure 1A) is the result of an intrinsic property of the PR8HA1 en-
velope. Interestingly, while IFITM3 did modestly inhibit VSV-g
pseudoparticle infection, this block was not alleviated by
AmphoB.
We next tested A549 human lung carcinoma cells expressing
high levels of exogenous IFITM3 and observed that AmphoB
(1 mM) produced a marked reversal of IFITM3-mediated restric-
tion at both 12 and 24 hr postinfection (Figure 1D; Figures
S1A–S1D). Similar results were seen with influenza B virus
(data not shown). Due to decreased toxicity, liposomal prepara-
tions of AmphoB (AmBisome) are used to treat patients with
fungal infections. Therefore, we investigated if AmBisome
also rescued IAV infection from IFITM3. This was the case, as
AmBisome’s effect on IFITM3-mediated restriction was indistin-
guishable from that of AmphoB at a clinically relevant concentra-
tion (2 mM; Figure 1E). Notably, therapeutically administered
maximal concentrations of AmphoB and AmBisome range
from 1 to 3 mM (Bellmann, 2007). Given IFITM3’s role in the
IFN response, we determined the effect of AmBisome on IFN-
a-induced restriction of IAV (Figure 1F). IFN-a inhibited IAV infec-
tion in both the vector and IFITM3 cells, with the addition of
AmBisome rescuing >60% of IAV infectivity, consistent with
the 60%–80% of the IFN response that is lost with IFITM3 deple-
tion (Brass et al., 2009). Thus, AmBisome removes themajority of
IFN’s protection from IAV in vitro.
A basic amine in the mycosamine of AmphoB is critical for its
antimycotic activity (Volmer and Carreira, 2010). This amine is
protonated at physiological pH and makes key interactions
with the lipid bilayer. Consequently, we synthesized DS-AmpB-
020, which incorporates additional cationic sites at the mycos-
amine (Figure 1G). Indeed, this compound displays 15-fold
more antifungal activity (Paquet et al., 2008). Treatment of
A549-IFITM3 cells with DS-AmpB-020 resulted in the complete
loss of IFITM3-mediated restriction and showed this
compound to be more potent than AmphoB (4-fold lower IC50;
Figure 1H). Together, these data suggest that the chemical
moieties required for the antifungal properties of these com-
pounds are also important for their alleviation of IFITM3’s
antiviral actions.
IFITM3 blocks IAV fusion and prevents vRNPs from translocat-
ing to the nucleus (Feeley et al., 2011). We examined the effect of
AmphoB on IAV vRNP nuclear translocation (Figure 2A). At the
start of infection, the IAV nucleoprotein (NP) is associated with
the vRNPs. By immunostaining for NP, we can follow vRNP dis-
tribution intracellularly. HeLa-vector or HeLa-IFITM3 cells were
chilled on ice with IAV PR8. Next, the viral supernatant was
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Figure 1. AmphoB Increases IAV Infection by Preventing IFITM3-Mediated Restriction In Vitro
(A) HeLa cells stably expressing either of two negative control short hairpin RNAs (shRNAs) against the firefly luciferase gene (shLuc-1 or shLuc-2) or shRNAs
against IFITM3 (shIFITM3-1 and shIFITM3-2) were incubated for 1 hr in the presence (red) or absence (blue) of 1 mM AmphoB, then challenged with IAV WSN/33
(multiplicity of infection [moi] 0.2) or PR8 (moi 0.02) followed by immunostaining for HA. Numbers represent the mean percentage of infected cells of three
separate experiments ± SD, as determined by imaging analysis software.
(B)Whole cell lysates from the indicated cells in (A)were subjected to immunoblottingusing thenotedantibodies. kDa, kilodaltons.RANserves asa loading control.
(C) IFITM3’s restriction of HA-mediated entry is overcome by AmphoB. A549 cells stably transduced with IFITM3 or with vector alone (Vector) were treated with 1
mMAmphoB (red) or buffer (blue) then challengedwith the indicated pseudotypedMLV-GFP particles:WSN/33 (H1), PR8 (H1), Thai (H5), FPV (H7), or the g protein
of VSV. Relative infection represents the percentage of GFP-positive cells normalized to that of A549-vector cells as determined by fluorescence-based imaging.
Results are the mean of three independent experiments ± SD.
(D and E) A549-vector (blue) or A549-IFITM3 (red) cells were infected with increasing amounts of IAV (WSN/33, relative moi) in the presence or absence of
AmphoB (D) or AmBisome (E). Infectivity was determined by immunostaining for surface HA protein.
(F) IAV infection (WSN/33,moi 2) ofA549-vector (blue) orA549-IFITM3 (red) cells in thepresence (closedsymbols) or absence (opensymbols) ofAmBisomeor IFN-a.
(G) Structure of the AmphoB derivative DS-AmpB-020.
(H) A549-vector (Vec, open symbols) or -IFITM3 (M3, closed symbols) cells were infected with IAV (WSN/33, moi 2) in the absence (buffer, green lines) or presence
of increasing concentrations of either AmphoB (blue) or DS-AmpB-020 (red).
Results are representative of three independent experiments.
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Figure 2. AmphoB Prevents IFITM2- and IFITM3-Mediated Restriction, but Not Restriction by IFITM1
(A) HeLa-vector or HeLa-IFITM3 cells were incubated with AmphoB or buffer for 1 hr prior to being incubated on ice with IAV PR8. Warm media was added at
time zero. Cells were fixed at the indicated time points, immunostained for the IAV NP protein (green) and stained for DNA, then analyzed by confocal
microscopy. Image analysis software was used to define each cell’s nuclear peripheries (blue lines based on the staining of nuclear DNA). Numbers represent
the number of NP particles (green) present per nucleus at the indicated time points and are the mean ± SD of three independent experiments. Scale bar,
10 mM.
(B) A549 cells stably transduced with vector alone (Vector) or with IFITM1 (M1), IFITM2 (M2), or IFITM3 (M3) were incubated for 1 hr with increasing concentrations
of AmphoB followed by infection with IAV WSN/33 for 12 hr and immunostaining for HA.
(C) Schematic diagram of the IFITM chimeras. The N- and C-terminal domains (NTD, CTD) and intramembrane domains 1 and 2 (IM1 and IM2) are shown,
separated by the conserved intracellular loop (CIL). M1, IFITM1 (gray); M2, IFITM2 (green); M3, IFITM3 (red). The chimeric proteins (M3M1 andM1M3) are shown
below, with the first M# representing the NTD’s origins and the second M# denoting the consignation of the remaining portion of the protein.
(D) A549 cells stably transduced with vector alone (Vector) or the indicated chimeras were incubated for 1 hr with increasing concentrations of AmphoB prior to
infection with IAV WSN/33 as above.
(E) Immunoblot of the indicated cell lines using the CIL antisera, which recognizes an epitope that is identical across all of the IFITM WT proteins and chimeras.
Results are representative of three independent experiments.
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replaced with warm media (0 min). At the indicated times after
warming, cells were evaluated for NP signal with a confocal
microscope. vRNPs arrive in the nuclei by 90 min in the vector
cells, with the NP signal increasing through to 120min, and these
events are inhibited by IFITM3 overexpression. Remarkably,
when we treated the cell lines with AmphoB, both the vector
and IFITM3 cells showed a strong increase in vRNP particles in
their nuclei, although the vector cells were still more infected at
90 min. A time of addition experiment showed that AmphoB’s
effect was maximal when added 60 min prior to viral addition,
consistent with inhibiting IFITM3 (Figure S1E). An immunoblot
revealed that AmphoB treatment did not decrease IFITM3 levels
(Figure S1F). Together with the pseudoparticle experiments,
these data demonstrate that AmphoB’s enhancement of IAV
infection arises from it overcoming IFITM3’s inhibition of viral
fusion.
To determine the specificity of AmphoB’s actions, we
compared its effect on A549 cells stably expressing IFITM1,
IFITM2, or IFITM3. These experiments showed that while
AmphoB effectively counteracts IFITM2 and IFITM3, its neutral-
ization of IFITM1 was considerably less, with only a 1.4-fold in-
crease in infection observed (Figure 2B). Next, chimeric IFITM
proteins were constructed to find what regions of IFITM3 confer
AmphoB sensitivity (John et al., 2013). IFITM3’s N-terminal
domain (NTD) was fused with the remaining portions of IFITM1
to generate M3M1, and the NTD of IFITM1 was fused to IFITM3
to produce M1M3 (Figure 2C). The M3M1 chimera was less
affected by AmphoB treatment similar to wild-type (WT) IFITM1,
and theM1M3 protein was rendered ineffective by AmphoB (Fig-
ure 2D). The levels of the WT IFITM proteins in the cell lines used
for these experiments were purposefully matched to the expres-
sion levels of the chimeras, resulting in less restriction than seen
with higher-expressing cell lines (Figure 2E). These results reveal
that AmphoB impacts IFITM2 and IFITM3 greater than IFITM1
and that this susceptibility resides in amino acids 51–133 of
IFITM3.
IFITM3’s mechanism of restriction is not fully understood.
Given that AmphoB reverses IFITM3’s inhibition of viral replica-
tion, we set about using it as a molecular probe to investigate
IFITM3’s actions. IAV fusion requires endosomal acidification,
and IFITM3 both blocks IAV fusion and increases intracellular
acidity by expanding the late endosomal and lysosomal com-
partments (Feeley et al., 2011). Therefore, IFITM3 might inhibit
IAV by altering endosomal pH. To test this idea, HeLa-vector
and HeLa-IFITM3 cells were stably transduced with a RAB7-
red fluorescent protein (RAB7-RFP) to identify their late endo-
somes and lysosomes. The cell lines were then incubated with
a mixture of two dextrans, conjugated to either a pH-sensitive
or pH-insensitive fluor, in the presence or absence of AmphoB.
Calculating the ratio of these two signals allowed us to determine
that IFITM3 increased the acidity in the RAB7 compartments
(Figure S2A). In addition, AmphoB modestly decreased the
relative acidity of both the vector and IFITM3 cell lines. We
next evaluated the consequences of AmphoB’s altering pH on
acid-induced HA activation. At the indicated times after the
initiation of a synchronized infection, we immunostained for the
presence of HA that has undergone an acid-induced conforma-
tional change required for fusion (Figure S2B). These experi-
ments showed more acid-induced HA signal in the IFITM3 cells,
consistent with their higher acidity. However, we observed no
appreciable change in the levels of acid-induced HA upon
AmphoB treatment of either cell line. Along with the dextran
and NP translocation studies, these results suggest that
AmphoB did not prevent IFITM3-mediated restriction by
decreasing endosomal acidity. These studies also showed that
the levels and location of IFITM3 were not altered by AmphoB
treatment with or without viral infection.
AmphoB’s pores permit the diffusion of ions across mem-
branes (Bolard, 1986). Endosomal membrane potential and ion
concentration (Na+, K+, and Cl) play roles in both endocy-
tosis and viral-hostmembrane fusion (Helenius et al., 1985; Scott
and Gruenberg, 2011). Therefore, we examined how IFITM3 and
AmphoB influence endosomal Na+ levels. Vector and IFITM3
cells were treated with AmphoB, nystatin (a related heptaen),
or three Na+ ionophores, then incubated with a cell-impermeable
fluorescent indicator, Asante Na+ green 2 (ANG-2). ANG-2 re-
mains in the endocytic compartment permitting the visualization
of Na+ levels in vital endosomes. The HeLa-IFITM3 cells showed
a higher ANG-2 signal than vector (normalized maximum ANG-2
intensity of IFITM3 cells = 1.28, vector = 1.0; p value = 2.2 3
105; Figure 3A), indicating that IFITM3 increases endosomal
salinity as well as acidity. Addition of the indicated compounds
after ANG-2 reduced the intensity of the Na+ signal in both cell
lines. However, the loss of IFITM3-mediated restriction was
seen only with AmphoB or nystatin treatment and not with any
of the ionophores (Figure 3B). Therefore, AmphoB’s diminish-
ment of endosomal Na+ concentration alone is unlikely to explain
its counteracting IFITM3-mediated restriction.
Nystatin, a pore-forming heptaen like AmphoB, was the only
other compound found to rescue IAV infection from IFITM3. In
contrast, the ionophores do not form pores but instead transport
Na+ by encasing the ion and shuttling it across the bilayer (Fig-
ure 3C). This difference suggests that egress of a combination
of ions (Cybulska et al., 1995; Hartsel et al., 1994), or the pore
itself may alter the membrane’s properties and underlie
AmphoB’s negation of IFITM3. To investigate this, we used
two small molecules, tetraethylammonium (TEA) and acetylcho-
line (ACh), to block AmphoB pores (Brutyan and McPhie, 1996;
Terazima and Yoshino, 2010; Figure 3C). We first determined
conditions where TEA or ACh prevented the AmphoB-mediated
efflux of Na+ from endosomes (Figure 3D; quantitation provided
in Figure S2C). Importantly, we assume from these results that
the diffusion of additional ions (i.e., K+ and Cl) through the
AmphoB pores is also blocked. In support of this, TEA also
diminished the modest change in endosomal acidity observed
with the addition of AmphoB (Figures S2A and S2D). Next, using
these conditions, we challenged the vector and IFITM3 cells with
IAV and found that the blockade of AmphoB pores with either
TEA or ACh had no effect on AmphoB’s rescue of IAV replication
(Figure 3E), arguing that alteration of endosomal ion concentra-
tion and pore conductance cannot account for either IFITM3-
mediated restriction or its negation by AmphoB.
Because AmphoB binds cholesterol and overcomes IFITM3-
mediated restriction, we were intrigued by recent studies
regarding the IFITMs and VAPA, cholesterol, and oleic acid;
therefore, we tested the role of these factors in IFITM3-mediated
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Figure 3. IFITM3’s Inhibition of IAV Is Overcome by AmphoB and Nystatin, but Not by Na+ Ionophores
(A) HeLa-vector or HeLa-IFITM3 cells were incubated with the indicated compounds and stained for endosomal sodiumwith the fluorescent indicator dye Asante
Na+ green 2 (ANG-2, green) and then imaged using confocal microscopy. The concentrations used were AmphoB 1 mM, nystatin 50 mM, and SI-X, SQI-Et, SQI-Pr
5 mM. Scale bar, 10 mm.
(B) IAV WSN/33 infection (moi = 2) of A549-vector (blue) or A549-IFITM3 (red) cells in the presence or absence of increasing concentrations of the indicated
compounds. Cells were treated with the indicated compounds for 1 hr prior to infection.
(legend continued on next page)
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inhibition of IAV infection. Confocal imaging using the choles-
terol-binding fluorescent probe filipin confirmed that overex-
pression of either IFITM1 or IFITM3 increased intracellular
cholesterol (Figures S3A–S3C; Amini-Bavil-Olyaee et al., 2013).
However, lowering the levels of intracellular cholesterol in A549
cells using methyl-b-cyclodextrin (MbCD) or lovastatin resulted
in no appreciable difference in restriction of IAV WSN/33 by
IFITM1 or IFITM3, with or without AmphoB treatment (Figure 4A).
The addition of cholesterol slightly decreased infection in the
vector cells and halved AmphoB’s alleviation of IFITM3-medi-
ated restriction, although we cannot rule out that the latter result
occurs because excess cholesterol prevents AmphoB from
reaching an effective intracellular concentration. Notably, treat-
ment of the A549 cell lines with oleic acid had no effect on either
IFITM1- or IFITM3-mediated restriction of IAV WSN/33 (Fig-
ure 4B). Overexpression of both VAPA and IFITM3 in A549 cells,
or VAPA alone in HeLa cells, generated a modest alleviation of
IFITM3-mediated restriction of either IAV PR8 or IAV WSN/33
infection (Figures 4D–4F). Neiman-Pick type c1 fibroblasts
contain a mutation that results in high levels of cholesterol in
late endosomal and lysosomal membranes, but this charac-
teristic did not diminish IAV WSN/33 infection (Figures 4G
and 4H; Amini-Bavil-Olyaee et al., 2013). Last, three alanine
scan (AS) mutant A549 proteins, each possessing six contiguous
residues changed to alanine collectively spanning the IM2 region
of IFITM3 that interacts with VAPA, had no loss in restriction
compared to WT IFITM3, nor did their respective mutations
result in any alterations in lysosomal cholesterol levels (Figures
S3D–S3G; John et al., 2013). These data suggest that neither
VAPA nor cholesterol nor the alleviation of a block to hemifusion
by oleic acid plays a substantial role in either IFITM3-mediated
restriction of IAV or its reversal by AmphoB.
The IFITM proteins can associate to form homo- and hetero-
meric complexes via their IM1 domains, and this interaction is
required for restriction of IAV (John et al., 2013). This prompted
us to hypothesize that the multimerization of IFITM proteins in-
hibits viral fusion by altering the fluidity of the cell membrane.
To test this idea, we measured the membrane fluidity of cells
stably expressing IFITM1 using fluorescence recovery after pho-
tobleaching (FRAP). We chose to use COS-7 cells stably trans-
duced with IFITM1 due to their planar morphology and because
IFITM1 is predominantly cell-surface expressed as compared to
IFITM3, which resides in late endosomes and lysosomes that
were not amenable to FRAP studies due to their small size and
continued movements (data not shown; Figure 5A; Figure S4A).
Caveolin 1 (CAV1) was chosen as a control because it has a
similar intramembrane topology to the IFITMs (Hoop et al.,
2012; Yount et al., 2012). After incubating the cells along with a
fluorescent membrane probe (DiO), we then photobleached an
area of the cell surface (white squares, Figure 5B). Wemonitored
the return of the DiO signal as readout for membrane fluidity by
capturing serial images of the bleached areas (Figure 5C). These
experiments showed that IFITM1 decreased membrane fluidity
compared to vector cells, signified by the slower recovery and
a greater than 2-fold increase in the immobile fraction in the
IFITM1 cells (Figure 5D). Consistent with previous reports, and
in contrast to IFITM1, CAV1 expression increased membrane
fluidity, demonstrating the specificity of IFITM1’s actions (Cai
et al., 2004). To test for a functional effect, we emulated elegant
studies that established that IAV and other fusogenic viruses can
induce tissue culture cells to form syncytia when exposed to low
pH (White et al., 1981, 1982). We incubated the COS-7 cell lines
(vector, IFITM1, and IFITM3) with concentrated IAV PR8 on ice,
followed by the addition of warm buffer at either pH 5.0 or 7.5.
After replacing the buffer with media, we stained the cells for
actin and DNA followed by image analysis. Quantitation of syn-
cytia, based on clustering of nuclei and the absence of inter-
vening bands of actin (Figure 5E), showed there were less fusion
events occurring among the IFITM1 cells (1.5% ± 0.4% fused
cells) as compared to either the IFITM3 cells or the vector control
cells (3.6% ± 0.6% fused cells, p < 0.05; Figures 5F and 5G). We
interpret the lack of effect by IFITM3 in this assay to be attribut-
able to its location in the late endosomes and lysosomes. The
levels of the exogenously expressed IFITM1 and IFITM3 proteins
were seen to be comparable by immunoblotting (Figure 5H).
AmphoB did not alter either IFITM1’s effect onmembrane fluidity
or its antifusion actions (Figures S4B and S4C), although this
was not altogether unexpected given AmphoB’s weak effect
on IFITM1-mediated restriction. Therefore, we conclude that
IFITM1 decreases membrane fluidity along with increasing resis-
tance to IAV-induced cell-to-cell fusion.
Our data demonstrate that AmphoB increases IAV replication
by overcoming IFITM3’s protective effects in vitro. To determine
the effects of AmphoB on IAV in vivo, we infected either WT or
Ifitm3 knockout mice (Ifitm3/) with a low-pathogenicity strain
of IAV (A/X-31 H3N2 [X-31]; (Everitt et al., 2012). At the dose
used, the X-31 strain produced a mild illness from which the
WT mice made a full recovery (Figures 6A and 6B). In contrast,
and consistent with our previous studies, the infected Ifitm3/
mice lost >25% of their body weight with signs of significant
illness 6 days postinfection. Notably, WT littermates treated
with AmBisome (3 mg/kg injected at days 0, 2, and 4 relative
to viral inoculation) behaved identically to the Ifitm3/ mice,
experiencing a clinical course usually observed with more
pathogenic strains of IAV and manifest by severe symptoms in
conjunction with a weight loss exceeding 25% of their starting
values. We saw no signs of illness with AmBisome treatment
alone in the absence of infection (Figure S5). Evaluation of lung
(C) Schematic diagram of AmphoB or nystatin transmembrane pores (left) permitting the passive diffusion of multiple monovalent cations (purple and red ovals)
across the endosomal membrane (arrow indicates high to low concentration gradient). In comparison, the ionophores selectively bind Na+ (red ovals) in a central
region, effectively shielding the positive charge from the hydrophobic interior of the membrane and thus allowing the cation to be transported down the gradient.
Adding TEA or ACh blocks the opening of the AmphoB pore, preventing ion transport (lower panel, gold oval).
(D) Confocal images of the relative levels of endosomal sodium based on the fluorescent signal of ANG-2 (green) in A549-vector or A549-IFITM3 cells with or
without treatment with AmphoB, TEA, or ACh. Quantitation provided in Figure S2C. Scale bar, 10 mm.
(E) IAVWSN/33 infection of A549-vector (blue) or A549-IFITM3 (red) cells in the presence or absence of AmphoB, TEA, or ACh. Serial dilutions of TEA or AChwere
added to cells 1 hr prior to infection. Results are representative of three independent experiments throughout.
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Figure 4. Role of Cholesterol or VAPA in IFITM-Mediated Restriction of IAV
(A) IAV WSN/33 infection (moi 1) of A549-vector (Vec), A549-IFITM1 (M1), or A549-IFITM3 (M3) cells, treated with the indicated small molecules, in the absence
(Buffer, blue) or presence of AmphoB (1 mM, red).
(B) IAV WSN/33 infection of A549-vector (blue), A549-IFITM1 (red), or A549-IFITM3 (green) cells treated with the indicated compounds prior to infection.
(C) HeLa cells were stably transduced with retroviruses expressing either a negative control shRNA against the firefly luciferase gene (shLuc-1), a shRNA against
IFITM3 (shIFITM3-1), or the VAPA cDNA (for the latter, two independently derived polyclonal cell populations, VAPA-1 and VAPA-2, are shown). Cells were then
treated with (red) or without IFN-a (blue) for 16 hr and then infected with IAV WSN/33. Results represent the mean of three independent experiments ± SD.
(D) Whole cell lysates from the indicated cells in (C) were subjected to immunoblotting using the indicated antibodies. RAN serves as a loading control.
(E) Infection of A549-vector (blue), A549-IFITM3 (red), or A549-IFITM3+VAPA (green) cells with increasing amounts of IAV PR8 (left) or IAVWSN/33 (right). Results
are representative of three independent experiments.
(legend continued on next page)
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pathology at day 6 postinfection showed marked edema, pneu-
monia, and hemorrhage with substantial inflammation in the
AmBisome-treated infected mice (either WT or Ifitm3/) as
compared to theWTmice not exposed to AmBisome (Figure 6C).
Indeed, in the setting of infection, there is little difference seen
when comparing the AmBisome-treated WT lungs to ones
from an Ifitm3/ animal.
Consistent with these results, mouse embryonic fibroblasts
(MEFs) derived from Ifitm3/ mice were more susceptible to
infection than WT MEFs, and this difference was largely erased
with AmphoB exposure (Figure 6D, E). Similar to above, the
Ifitm3/ cells treated with AmphoB demonstrated a slightly
increased infection with X-31, suggesting that Ifitm2 or an addi-
tional component is also being overcome by AmphoB. We
conclude that a clinical formulation of AmphoB, AmBisome, pro-
duces the functional equivalent of an Ifitm3-null state, and by so
doing converts a mild illness into a life-threatening infection.
DISCUSSION
We began this study with the observation that treating cells with
AmphoB prevented IFITM3-mediated restriction. Upon investi-
gating this phenomenon, we found that overcoming IFITM3 is
a principal component of AmphoB-enhanced IAV infection,
both confirming and significantly extending a previous study
reported during this investigation (Roethl et al., 2011). Of conse-
quence, we also showed that by neutralizing IFITM3’s block to
viral fusion, AmphoB removed more than 60% of IFN’s protec-
tive effects against IAV in vitro.
We also used AmphoB as a molecular probe to investigate the
mechanism of IFITM3-mediated restriction and determined that
while IFITM3 increases both endosomal acidity and salinity,
these events are unlikely to play major roles in restriction.
Instead, these properties may all arise from the same mecha-
nism, specifically that IFITMs alter the physical properties of
membranes. In support of this idea, we determined that IFITM1
decreases membrane fluidity and that this event is associated
with inhibition of IAV-induced cell-to-cell fusion; these data are
consistent with those recently generated using orthologous
approaches (Li et al., 2013). Collectively, these findings have
several implications. First, by decreasing membrane fluidity,
IFITMs may impede the sequential assembly of viral-host recep-
tor complexes, thereby blocking viral entry. Viruses that rely on
multiple receptors for entry would be susceptible to this effect
(e.g., HCV and HIV-1). Consistent with this, IFITM1 inhibits
both HCV and HIV-1 (Schoggins et al., 2011; Wilkins et al.,
2013), and a separate study has reported that the restricted
mobility of one of the two HIV-1 host receptors, CD4, can inhibit
viral fusion (Rawat et al., 2008). Similarly, recent work has
elegantly shown that the clustering of multiple viral envelopes
is needed for IAV entry, suggesting that this activity may be hin-
dered by IFITMs residing in the host-derived viral and/or host
membranes (Ivanovic et al., 2013). Second, IFITM homo- and
heteromers within the membrane may stabilize membrane com-
plexes by inhibiting dissociation, i.e., stabilizing the vacuolar
ATPase may increase endosomal acidity and potentially salinity
(Wee et al., 2012). Third, the insertions of each IFITM’s IM do-
mains into the cytosolic-facing leaflet of the membrane may pro-
duce a positive curvature in the bilayer as well described for
othermembrane-associated proteins (Callan-Jones andBasser-
eau, 2012; Nikolaus and Herrmann, 2012; Voeltz et al., 2006;
Yount et al., 2012). Therefore, by producing a concave and rigid
membrane, the IFITM proteins may create a barrier for the viral
fusion machinery. Notably, using such a general strategy to pro-
tect oneself from many viruses would produce multiple fitness
advantages.
Given thesemodels of IFITM3-mediated restriction, we favor a
scenario wherein AmphoB rescues IAV replication by increasing
membrane fluidity and planarity; this would permit viral-host re-
ceptor interactions and pore formation. In support of this notion,
it has been reported that AmphoB enhances membrane fluidity
(Abu-Salah, 1991; Henry-Toulme´ et al., 1989;Younsi et al.,
2000). As mentioned, AmphoB first binds to cholesterol in the
lipid bilayer and then forms transmembrane pores. A more
cationic analog of AmphoB, DS-AmpB-020, was more potent
against IFITM3, which likely arises from its improved hydrogen-
bonding ability, which could augment either channel formation
or interactions with negatively charged phospholipids to in-
crease membrane fluidity. We have shown that blocking pore
conductance does not alter AmphoB’s effects on restriction.
Therefore, fenestration of the lipid bilayer by pores formed by
either AmphoB or DS-AmpB-020 may be increasing membrane
fluidity. In addition, the presence of these heptaenes in themem-
brane may disrupt cholesterol-phospholipid interactions and/or
IFITM interactions, leading to increased membrane flexibility
(Figure 6F). In support of this last assertion, we found that adding
additional cholesterol reduced by the half the alleviation of
IFITM3 restriction by AmphoB.
We note, however, that AmphoB did little to alleviate either
IFITM1’s antiviral action or it’s inhibitory effect on membrane
fluidity and cell-to-cell fusion. Therefore, additional efforts will
be needed to determine if the effect of IFITM1 on plasma mem-
brane fluidity is the same as the effect of IFITM3 on endosomal
membranes and if AmphoB’s antagonism of IFITM3 results
from alterations in membrane fluidity. In this regard, we are un-
sure as to why AmphoB specifically overcomes IFITM2 and
IFITM3 while leaving IFITM1’s actions predominantly extant.
One factor may be proximity, because AmphoB is endocytosed
quite rapidly leading to its concentration in the late endosomes
and lysosomes, the areas of IFITM3’s highest concentrations.
Future studies using derivatives of AmphoB and IFITM mutant
proteins will be useful in further testing such models.
Intrigued by recent reports, we tested the role of VAPA,
cholesterol, and oleic acid in IFITM3-mediated restriction. Over-
expression of VAPA modestly decreased IFITM3-mediated
restriction of IAV in our assays. Based on our use of the same
(F) Whole cell lysates from the indicated cells in (E) were subjected to immunoblotting using the indicated antibodies. Actin serves as a loading control.
(G) Niemann-Pick type c1 (NPC) or wild-type (WT) primary human fibroblasts infected with the indicated IAVs with or without AmphoB (Ampho) treatment.
(H) Confocal images of primary human fibroblasts in (G) stained with filipin (white) to detect cholesterol and immunostained for LAMP1 (red) to identify the late
endosomal and lysosomal compartments. Scale bar = 15 mM.
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Figure 5. IFITM1 Decreases Membrane Fluidity and Inhibits Cell-to-Cell Fusion
(A) COS-7 cells were stably transduced with retroviruses expressing the empty vector (Vector), IFITM1, CAV1-teal fluorescence protein (TFP), or IFITM3. Cells
were then confocally imaged to detect the expressed proteins (all in green; additional specificity control images in Figure S4A). Nuclear DNA was stained with
DAPI (blue). Scale bar, 10 mM.
(B) Fluorescence recovery after photobleaching of the plasma membrane. COS7-vector or COS7-IFITM1 cells were stained with DiO and the unbound dye
removed. Cells were photobleached in the indicated area (white square) with a 488 laser, and a series of pictures out to 95 s postbleach were taken. Images are
shown for prebleach, postbleach, and 17 s postbleach (t1/2 of IFITM1 recovery).
(C) COS7-vector, COS7-CAV1, or COS7-IFITM1 cell fluorescence recovery was quantified using Leica Lite software, with each individual time point representing
the average of ten normalized readouts. PRISM software was then used to plot the best-fit exponential decay line. Results are representative of three independent
experiments.
(legend continued on next page)
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cell line, A549, and antibody against VAPA as the seminal report,
we estimate that our overexpression of VAPA met or surpassed
the published levels. Modulation of cholesterol levels had no
appreciable effect on IFITM3-mediated restriction, suggesting
that cholesterol mislocalization does not contribute to VAPA’s
antagonism of IFITM3. Furthermore, cells expressing either of
three IFITM3 proteins containing mutations that span IM2, the
reported interaction domain of IFITM3 with VAPA, exhibited
WT levels of restriction and intracellular cholesterol. These re-
sults suggest that a direct interaction between VAPA and IFITM3
does not underlie the subtle effect of VAPA on restriction. We
mention, however, that our alanine scanning strategy may have
been too conservative because IM2 is a hydrophobic domain.
We also addressed the role of oleic acid in overcoming IFITM-
mediated inhibition of cell-to-cell fusion. Specifically, we found
that oleic acid cannot overcome IFITM1- or IFITM3-mediated re-
striction of IAV in vitro under the conditions tested. Furthermore,
oleic acid did not overcome IFITM1-mediated inhibition of
cell-to-cell fusion assays by IAV particles (data not shown).
Therefore, while these recent reports have improved our under-
standing of IFITM3-mediated restriction, we conclude that addi-
tional mechanistic studies are required.
When we found that AmphoB prevented IFITM3’s antiviral
actions, it suggested that patients treated with AmphoB formu-
lations might be at greater risk for influenza (Everitt et al.,
2012). Therefore, we tested a clinical preparation of AmphoB,
AmBisome, in vivo and found that similar to Ifitm3/ mice, WT
littermates treated with AmBisome developed severe illness
from a normally nonpathogenic IAV strain. Individuals with a
variant of IFITM3 aremore likely to be hospitalized with influenza,
suggesting that IFITM3 plays a role in protecting human popula-
tions (Everitt et al., 2012); indeed, this IFITM3 allele (rs12254-C)
was recently reported to convey a large population-attributable
risk of 54.25% in the Chinese population (Zhang et al., 2013).
Moreover, IFITM3 is critical for protecting CD8+ resident memory
T cell populations during IAV infections in vivo, arguing that
AmphoB’s antagonism of IFITM3 may impair the adaptive im-
mune system as well (Wakim et al., 2013). Collectively, these
data suggest that patients receiving antifungal therapy with lipo-
somal AmphoB may be functionally immunosuppressed and
therefore more vulnerable to influenza. Many patients receiving
AmBisome have lost their adaptive and innate immune defenses,
so the role of intrinsic immune factors may be critical in protect-
ing them against IAV (Moen et al., 2009). In addition, some of
these patients are also on prophylactic AmBisome therapy and
so may potentially be incurring greater IAV infection risks. It is
our hope that the reporting of the mechanism and the in vivo
consequences of this interaction between IFITM3 and ampho-
tericin B may help stimulate translational studies and potentially
guide patient care.
EXPERIMENTAL PROCEDURES
Tetraethylammonium and Acetylcholine Experiment
Tetraethylammonium (TEA, 5 mM, Sigma) and acetylcholine (ACh, 5 mM,
Sigma) were incubated with A549 cells with or without 1 mM of AmphoB at
37C for 1 hr. prior to infection with WSN/33. After infection, cells were incu-
bated at 37C for 12 hr. then fixed and analyzed as described previously.
NP and Acid-Induced HA Translocation Experiments and Confocal
Imaging
Experiments for detection of NP nuclear translocation or acid-induced HA
conformational change were modified from previously described experiments
(Feeley et al., 2011). Nuclear translocation of vRNPwas quantified by analyzing
images using Imaris 7.1 (Bitplane scientific software) as previously described.
Cell-to-Cell Fusion Assay
Vector, IFITM1, or IFITM3 COS-7 cells and PR8 virus were chilled on ice before
the addition of virus to cells (White et al., 1981, 1982). Virus and cells were incu-
bated at 4C for 40min. Cells were then rinsed and incubated with 37CpH 5.0
or pH 7.5 buffer (10 mM of MES and 10 mM of HEPES in 13 PBS) for 5 min.
Subsequently, the buffers were replaced with warm media and the cells incu-
bated in a 37C incubator for an additional 5 hr. Cells were then fixed with 4%
paraformaldehyde, permeabilized with 0.2% Triton X-100, and stained with
Alexa Fluor 594-conjugated phalloidin (1:500, Life Technologies) and Hoechst
33342 (1:10,000, Invitrogen) before imaging. Fusion events were identified
based on the formation of syncytia and nuclear aggregation. The percentage
of fusion was calculated using a ratio of the nuclei within fused cells over the
total nuclei for each microscopic field evaluated with more than five fields
examined for each experimental condition.
FRAP
Cells were plated on glass-bottom 6cmdishes (MatTek) 16 hr prior to analysis.
Cells were pretreated with fresh media or fresh media containing 1 mM of
AmphoB for 1 hr then stained with Vibrant DiI or DiO (Invitrogen) for 15 min
at 37C, then washed with 13 PBS twice. FRAP was then done on the cells
using a Leica SP5 with the Leica FRAP wizard. At least ten cells were
measured per experiment, and LAS AF Lite (Leica) software was used to quan-
tify the intensity of the photobleached area, the total cell fluorescence, and an
area outside of the cells for normalization. The normalized intensities of the
photobleached areas were then averaged together to form a representative
curve of each condition.
Live Cell Imaging
Cells were plated onto chambered coverglass slides (Thermo Fisher Scientific)
and cultured overnight. Before imaging, cells were incubated at 37C for 1 hr
with 5 mM of yellow/blue dextran (Life Technologies, 10,000 MW, L-22460) or
5 mM of Asante sodium green (TefLabs) in the presence or absence of 1 mM of
(D) The COS7-vector, COS7-CAV1, or COS7-IFITM1 percent immobile fraction was calculated by first subtracting the normalized average of the 95 s postbleach
images, then subtracting those values from 1 to determine the amount of membrane that did not recover. Results are representative of three independent
experiments.
(E) Schematic of IAV-induced cell-to-cell fusion assay. Individual cells (lower portion) exhibit distinct boundaries of actin (red lines) and clearly spaced nuclei (blue
ovals). By comparison, after incubation with IAV and the addition of pH 5.0 buffer, the individual cells fuse and form syncytia, which possess multiple clustered
nuclei with no intervening actin boundaries.
(F) IAV-induced cell-to-cell fusion assay. Chilled IAV (PR8, moi 500–1,000) was incubated with the indicated stably transduced COS-7 cell lines from (A). Warm
buffer of either pH 5.0 or 7.5 was added, followed by warmmedia. Cells were incubated for 5 hr and then fixed and stained to monitor fusion events for both actin
(phalloidin, red), to highlight cellular boundaries (white dashed lines), and DNA (blue), to detect closely clustered nuclei present in syncytia. Scale bar, 10 mm.
(G) Percentage of fused cells in experiments using pH 5.0 buffer in (F). Fusion events per 100 nuclei were calculated and values represent the average of three to
five images from each of three independent experiments ± SD.
(H) Immunoblot of the indicated cell lines from (A). The CIL antisera recognize an epitope that is identical in both IFITM1 and IFITM3.
Cell Reports 5, 895–908, November 27, 2013 ª2013 The Authors 905
Figure 6. AmBisome Increases Influenza Morbidity and Mortality
(A and B) Change in bodymass (A) and survival (B) of WT and Ifitm3/mice with or without intravenous administration of AmBisome (3mg/kg) on days 0, 2, and 4
relative to intranasal inoculation with IAV X-31 (10,000 pfu); n > 3.
(C) WT and Ifitm3/ mice were treated or not treated with AmBisome and then challenged with X-31 influenza as above. At day 6 postinfection, lung sections
were prepared and stained with hematoxylin and eosin.
(D) The indicated MEFs were incubated for 1 hr in the presence (red, +) or absence (blue, ) of 1 mM AmphoB and then challenged with X-31 or pandemic
A/California/7/2009 (pH1N1) followed by fixation and immunostaining for NP. Numbers represent the mean percentage of infected cells of three separate
experiments ± SD.
(E) Immunoblot of the indicated cell lines from (D).
(F) Model of IFITMs inhibiting viral fusion. Top panels depict HA-directed membrane fusion. Insertion of the viral fusion peptide (red) by the HA protein into the
host’s endosomal membrane is followed by an acid-induced conformational change in HA producing a hemifusion transition state (middle, arrows represent force
(legend continued on next page)
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AmphoB, 5 mM of ionophores, or 1 mM of AmphoB ± TEA or ACh. Cells were
then visualized with confocal microscopy. For the ratiometric dextran experi-
ments, we calculated the average ratios of pH-sensitive dextran signal to
pH-insensitive dextran signal in the RAB7-RFP compartment normalized to
this same ratio as determined for the vector-RAB7-RFP control cells.
Mouse Infection
Background-matched wild-type (>95% C57BL/6) and Ifitm3/ mice (Everitt
et al., 2012) 8 to10 weeks of age were maintained in accordance with UK
Home Office regulations, UK Animals Scientific Procedures Act 1986 under
the project license PPL80/2099 (Everitt et al., 2012). This license was reviewed
by The Wellcome Trust Sanger Institute Ethical Review Committee. Groups of
more than five isoflurane-anaesthetized mice of both genotype were intrana-
sally inoculated with 1 3 104 plaque-forming units of X-31 influenza in 50 ml
of sterile PBS (Everitt et al., 2012). On days 0, 2, and 4, the AmBisome-
treated mice (wild-type or matched Ifitm3/) were administered 3 mg/kg of
AmBisome (Gilead) intravenously. Their weight was recorded daily and they
were monitored for signs of illness. Mice exceeding 25% total weight loss
were euthanized in accordance with UK Home Office guidelines. Littermate
controls were used in all experiments.
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increasing membrane fluidity and planarity, thereby permitting fusion pore formation.
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